Alicia Gilsenan

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter by Year

Filter by Publication Type

Filter by Publication Topic

Search Results

Physician awareness of the safe use of cyproterone acetate in Europe: A survey on the effectiveness of additional risk minimization measures

Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers

Abstracts of ICPE 2023, the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Halifax, Canada, 25-27 August 2023 Abstracts

Abstracts of ICPE 2023, the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Halifax, Canada, 25-27 August 2023 Abstracts

Post-authorization safety studies of acute liver injury and severe complications of urinary tract infections in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting

Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting

Risk of major cardiovascular and cerebrovascular events in users of Lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: A population-based cohort study

Teriparatide and osteosarcoma risk: History, science, elimination of boxed warning, and other label updates

Adapting to the dynamic landscape of the COVID-19 pandemic: Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community, August 26-28, 2022, Copenhagen, Denmark

Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study

Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: A literature review

Identification and validation of major cardiovascular events in the United Kingdom data sources Included in a multi-database post-authorization safety study of prucalopride

Real-world evidence: Patient views on asthma in respiratory specialist clinics in America

Long-term cancer surveillance: Results from the Forteo Patient Registry Surveillance Study

Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom

Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data

No evidence of off-label use of olodaterol and indacaterol in Denmark, France, and the Netherlands: A drug utilization study

Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350

Cardiovascular safety of prucalopride in patients with chronic constipation: A multinational population-based cohort study